Log in to save to my catalogue

Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a r...

Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a r...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a759a9d1a47644199691b4dde0ea0cb8

Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial

About this item

Full title

Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2025-01, Vol.16 (1), p.553-10, Article 553

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Combined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT and ICB is unknown. NRG-GY017 (NCT03738228) was a randomized phase I trial of atezolizumab (anti-PD-L1) neoadjuvant and concurrent with CRT (Arm A) vs. concurrent with CRT (Arm B) in p...

Alternative Titles

Full title

Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_a759a9d1a47644199691b4dde0ea0cb8

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a759a9d1a47644199691b4dde0ea0cb8

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-024-55200-2

How to access this item